A comprehensive 2026 guide to UK online casinos with a 400% bonus. Understand wagering, find the best offers, and see if a 4x match is actually worth it. Read our full guide to 400% casino bonuses
OrbusNeich Announces Enrollment of First Patient in Japan Clinical Trial for its Proprietary Drug-Coated Balloon
OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty…
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also…
Siloam International Hospitals Receives Magnet with Distinction(TM), Highest Global Standard for Nursing Excellence
Southeast Asia’s Only Hospital Network with Two Hospitals Receiving Distinction Siloam International Hospitals has again been recognised at the highest level with two of its hospitals receiving Magnet® with Distinction…
Avantor India Appointed as Exclusive Distributor for Sartorius Filter Papers to Serve India’s Laboratory Consumables Sector
Avantor, a leading global provider of mission-critical products and services to the life sciences and advanced technology industries,announced today it has been appointed the exclusive distributor of Sartorius Filter Papers…
Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China
June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use…
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, further enhancing patient access to the medication
Everest Medicines (HKEX 1952.HK) announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, which were approved by the National…
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the Product), a Class 1 therapeutic biological…
Accrelist Appoints Derek Cheong as Chief Executive Officer
Group sharpens focus on aesthetics retail under the CEO’s first initiative, a proposed entry into the Xiamen aesthetic clinic market Accrelist Ltd. (“Accrelist” or the “Company”, together with its subsidiaries,…
Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the development and commercialization of DMX-200 in Greater China (Chinese mainland,…
iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival
iHerb, a global e‑commerce platform specializing in health and wellness products, has officially launched its 2026 “618 Peak Shopping Festival.” As a brand with a 29‑year heritage, this initiative brings…
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation
HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of…
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (Mabworks), under which the Company has obtained exclusive rights for…
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also…
Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit
Everest Medicines announced that its substantial shareholder, CBC Group, purchased 600,500 ordinary shares of the Company on the market from 20 May 2026 to 21 May 2026. The total consideration…
Graphene quantum dots show promise in targeting Parkinson’s-related protein clumping
Engineered carbon-based nanomaterials can interfere with the aggregation of misfolded proteins linked to neurodegenerative diseases, offering a new direction for future therapeutic exploration. The buildup of a protein called -synuclein…
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence
Everest Medicines (HKG: 1952) announced that on 14 May 2026, based on strong confidence in the company’s future prospects and long-term development, Mr. Wei Fu, a non-executive Director, the honorary…
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program
Highlights: WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare…
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
Highlights: According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare…
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully
Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the…
International Healthcare Week opens today, fuelling healthcare breakthroughs
ASGH and Medical Fair open concurrently, showcasing cutting-edge AI, Robotics and MedTech The fifth International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), opens today, featuring…